Protection induced by recombinant vaccinia virus targeting the ROP4 of Toxoplasma gondii in mice
Authors:
- 10 January 2025
- journal article
- research article
- Published by Elsevier in Experimental Parasitology
- Vol. 269, 108900
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonatesVaccine, 2021
- Toxoplasma: Immunity and PathogenesisCurrent Clinical Microbiology Reports, 2019
- Assessment of the antigenic and neuroprotective activity of the subunit anti-Toxoplasma vaccine in T. gondii experimentally infected miceVeterinary Parasitology, 2018
- Modified Vaccinia Virus Ankara2017
- Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal routeMedical Microbiology and Immunology, 2016
- Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategiesProtein & Cell, 2015
- Acute exacerbation of Toxoplasma gondii infection after hematopoietic stem cell transplantation: five case reports among 279 recipientsInternational Journal of Hematology, 2013
- Toxoplasma gondii: The immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosisExperimental Parasitology, 2009
- Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodiesVirology, 2004
- Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccinationVaccine, 1993